Phaseline

Companies › Poseida Therapeutics

Poseida Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Mar 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
P-BCMA-ALLO1
allogeneic BCMA-targeted CAR-T cell therapy
BCMAPhase 1Multiple MyelomaMar 2029
P-CD19CD20-ALLO1
Allogeneic CAR-T cells targeting CD19 and CD20
CD19, CD20Phase 1Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedMar 2029
P-MUC1C-ALLO1
Allogeneic CAR-T cell therapy targeting MUC1-C
MUC1Phase 1Breast CancerApr 2039

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04960579P-BCMA-ALLO1Phase 1Multiple MyelomaOncologyMar 2029
NCT06014762P-CD19CD20-ALLO1Phase 1Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedOncologyMar 2029
NCT03741127P-BCMA-ALLO1Phase 1Multiple MyelomaOncologyAug 2032
NCT05239143P-MUC1C-ALLO1Phase 1Breast CancerOncologyApr 2039

Targets

BCMA (1) MUC1 (1) CD19 (1) CD20 (1)

Companies with the same targets

Chongqing Precision Biotech Gilead Sciences AstraZeneca Bristol-Myers Squibb iCell Gene Therapeutics Roche Kali Therapeutics Shanghai AbelZeta Allogene Therapeutics Miltenyi Biomedicine

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.